NEWARK, Calif. --(BUSINESS WIRE)--Feb. 25, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the

- Conference call and webcast today at 4:30 p.m. ET - NEWARK, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product,

Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET NEWARK, Calif. --(BUSINESS WIRE)--Feb. 14, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator

NEWARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2020-- Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0 million aggregate principal

  NEWARK, Calif. --(BUSINESS WIRE)--Feb. 10, 2020-- Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it intends to offer, subject to market

- Prescription Drug User Fee Act (PDUFA) target action date of November 25, 2020 - NEWARK, Calif. --(BUSINESS WIRE)--Feb. 6, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation

- TEOXANE SA RHA® portfolio: first and only range of FDA -approved dermal fillers for correction of dynamic wrinkles - - Revance gains access to the growing $1.1B U.S. filler market with three differentiated products, and plans to launch in second quarter 2020 - - Fast-tracks Revance’s commercial

NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P.

NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update and shared anticipated

DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction NEWARK, Calif. --(BUSINESS WIRE)--Dec. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic